Zobrazeno 1 - 10
of 768
pro vyhledávání: '"Rozenbaum MH"'
Autor:
Perdrizet JE; Global Value and Evidence, Pfizer Canada, Kirkland, QC, Canada. Johnna.Perdrizet@pfizer.com., Rozenbaum MH; Global Value and Evidence, Pfizer B.V., Rotterdam, Netherlands., Heffler MJ; Ipsos Insight LLC, Norwalk, CT, USA.
Publikováno v:
Infectious diseases and therapy [Infect Dis Ther] 2024 Sep; Vol. 13 (9), pp. 2017-2034. Date of Electronic Publication: 2024 Jul 26.
Autor:
Rozenbaum MH; Value and Evidence Team, Pneumococcal Vaccines, Pfizer Inc., Capelle a/d Ijssel, The Netherlands. mark.rozenbaum@pfizer.com., Chilson E; Pfizer Inc., Collegeville, PA, USA., Farkouh R; Pfizer Inc., Collegeville, PA, USA., Huang L; Pfizer Inc., Collegeville, PA, USA., Cane A; Pfizer Inc., Collegeville, PA, USA., Arguedas A; Pfizer Inc., Collegeville, PA, USA., Tort MJ; Pfizer Inc., Collegeville, PA, USA., Snow V; Pfizer Inc., Collegeville, PA, USA., Averin A; Avalere Health, Boston, MA, USA., Weycker D; Avalere Health, Boston, MA, USA., Hariharan D; Avalere Health, Boston, MA, USA., Atwood M; Avalere Health, Boston, MA, USA.
Publikováno v:
Infectious diseases and therapy [Infect Dis Ther] 2024 Apr; Vol. 13 (4), pp. 745-760. Date of Electronic Publication: 2024 Mar 16.
Autor:
Rozenbaum MH; Pfizer, Capelle a/d Ijssel, Netherlands. Electronic address: mark.rozenbaum@pfizer.com., Huang L; Medial Development & Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA, United States., Perdrizet J; Pfizer, Inc., New York, NY, United States., Cane A; Medial Development & Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA, United States., Arguedas A; Medial Development & Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA, United States., Hayford K; Medial Development & Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA, United States., Tort MJ; Medial Development & Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA, United States., Chapman R; Evidera, UK., Dillon-Murphy D; Evidera, UK., Snow V; Medial Development & Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA, United States., Chilson E; Medial Development & Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA, United States., Farkouh RA; Pfizer, Inc., New York, NY, United States.
Publikováno v:
Vaccine [Vaccine] 2024 Jan 25; Vol. 42 (3), pp. 573-582. Date of Electronic Publication: 2024 Jan 07.
Autor:
Rozenbaum MH; Pfizer Inc., Collegeville, PA, USA., Huang L; Pfizer Inc., Collegeville, PA, USA., Cane A; Pfizer Inc., Collegeville, PA, USA., Arguedas A; Pfizer Inc., Collegeville, PA, USA., Chapman R; Evidera, London, UK., Dillon-Murphy D; Evidera, London, UK., Tort MJ; Pfizer Inc., Collegeville, PA, USA., Snow V; Pfizer Inc., Collegeville, PA, USA., Chilson E; Pfizer Inc., Collegeville, PA, USA., Farkouh R; Pfizer Inc., Collegeville, PA, USA.
Publikováno v:
Journal of medical economics [J Med Econ] 2024 Jan-Dec; Vol. 27 (1), pp. 644-652. Date of Electronic Publication: 2024 Apr 19.
Autor:
Rozenbaum MH; Pfizer Inc., Capelle a/d IJssel, The Netherlands., Begier E; Pfizer Vaccines, Dublin, Ireland. Elizabeth.Begier@pfizer.com., Kurosky SK; Pfizer Inc., New York, NY, USA., Whelan J; HEOR Ltd, Cardiff, UK., Bem D; HEOR Ltd, Cardiff, UK., Pouwels KB; University of Oxford, Oxford, UK., Postma M; University of Groningen, Groningen, The Netherlands., Bont L; University Medical Center Utrecht, Utrecht, The Netherlands.
Publikováno v:
Infectious diseases and therapy [Infect Dis Ther] 2023 Jun; Vol. 12 (6), pp. 1487-1504. Date of Electronic Publication: 2023 May 23.
Autor:
Li X; Global Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA., Warren S; Global Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA., Rozenbaum MH; Health Economics and Outcomes Research, Pfizer Inc., Capelle aan den Ijssel, The Netherlands., Perdrizet J; Global Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA. Johnna.perdrizet@pfizer.com.
Publikováno v:
Infectious diseases and therapy [Infect Dis Ther] 2023 Mar; Vol. 12 (3), pp. 997-1006. Date of Electronic Publication: 2023 Mar 03.
Autor:
Rozenbaum MH; Pfizer bv, Capelle aan den IJssel, The Netherlands., Judy J; Pfizer Inc, New York, NY, USA. Jennifer.Judy@pfizer.com., Tran D; EVERSANA, Burlington, ON, Canada., Yacisin K; Pfizer Vaccines, Collegeville, PA, USA., Kurosky SK; Pfizer Inc, New York, NY, USA., Begier E; Pfizer Vaccines, Dublin, Ireland.
Publikováno v:
Infectious diseases and therapy [Infect Dis Ther] 2023 Feb; Vol. 12 (2), pp. 677-685. Date of Electronic Publication: 2023 Jan 27.
Autor:
Rozenbaum MH; Health Economics and Outcomes Research, Pfizer, Capelle aan den Ijssel, The Netherlands. Mark.rozenbaum@pfizer.com., Perdrizet J; Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA., Li X; Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA., Wasserman MD; Patient and Health Impact, Pfizer Inc, New York, NY, USA., Grant LR; Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer Inc, New York, NY, USA., Hayford K; Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer Inc, New York, NY, USA., Farkouh RA; Health Economics and Outcomes Research, Pfizer, Capelle aan den Ijssel, The Netherlands.
Publikováno v:
Infectious diseases and therapy [Infect Dis Ther] 2023 Jan; Vol. 12 (1), pp. 295-298. Date of Electronic Publication: 2022 Nov 14.
Autor:
Schöttler MH; Health-Ecore B.V., Zeist, The Netherlands; Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands. Electronic address: marcelschottler@health-ecore.com., Coerts FB; Pfizer, Capelle a/d Ijssel, The Netherlands., Postma MJ; Health-Ecore B.V., Zeist, The Netherlands; Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands; Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, Groningen, The Netherlands., Boersma C; Health-Ecore B.V., Zeist, The Netherlands; Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands; Department of Management Sciences, Open University, Heerlen, The Netherlands., Rozenbaum MH; Pfizer, Capelle a/d Ijssel, The Netherlands.
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2023 Jan; Vol. 26 (1), pp. 91-98. Date of Electronic Publication: 2022 Aug 04.
Autor:
Rozenbaum MH; Pfizer Inc., Rivium Westlaan 142, 2909 LD, Capelle aan den IJssel, The Netherlands., Garcia A; Ingress-health, Weena 316-318 3012 NJ, Rotterdam, The Netherlands., Grima D; Eversana Life Science Services, 204-3228 South Service Road, Burlington L7N 3H8 ON, Canada., Tran D; Eversana Life Science Services, 204-3228 South Service Road, Burlington L7N 3H8 ON, Canada., Bhambri R; Pfizer Inc., 235 E 42nd St, New York, NY, USA., Stewart M; Pfizer Inc., 235 E 42nd St, New York, NY, USA., Li B; Pfizer Inc., 235 E 42nd St, New York, NY, USA., Heeg B; Ingress-health, Weena 316-318 3012 NJ, Rotterdam, The Netherlands., Postma M; Unit of PharmacoEpidemiology & PharmacoEconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.; Unit of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, Nettelbosje 2, 9747 AE, Groningen, The Netherlands.; Department of Health Sciences, University of Groningen, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen NL, The Netherlands., Masri A; The Amyloidosis Center, Knight Cardiovascular Institute, Oregon Health & Science University, 3303 S Bond Ave Building 1, 9th Floor, Portland, OR 97239, USA.
Publikováno v:
European heart journal. Quality of care & clinical outcomes [Eur Heart J Qual Care Clin Outcomes] 2022 Aug 17; Vol. 8 (5), pp. 529-538.